Mechanism of Action
Membrane Disruption
Magainins are positively charged (+4 net charge at physiological pH) and selectively bind anionic bacterial membranes over neutral mammalian membranes. They adopt an amphipathic alpha-helical conformation upon membrane contact and insert into the lipid bilayer. At threshold concentrations, they form toroidal pores or cause carpet-like membrane disruption, dissipating membrane potential and releasing cellular contents. This mechanism is distinct from protein-targeting antibiotics, conferring broad-spectrum activity.
Selectivity for Bacteria
Bacterial membranes are enriched in anionic phospholipids (phosphatidylglycerol, cardiolipin) and have high transmembrane potential (-130 to -180 mV), promoting magainin binding and insertion. Mammalian cell membranes contain zwitterionic phosphatidylcholine and cholesterol, which inhibit magainin insertion. This electrostatic selectivity gives a therapeutic window for topical antimicrobial application.
Research Summary
Pexiganan (MSI-78) Clinical Development
Clinical EvidencePexiganan, a 22-amino acid analog of magainin-2 with enhanced stability and activity, completed two Phase III trials for mildly infected diabetic foot ulcers (DFU). It demonstrated non-inferiority to oral ofloxacin in clinical cure rates. The FDA initially issued a non-approvable letter in 1999; a new NDA was filed by Dipexium Pharmaceuticals in 2013 and subsequently resubmitted, with Phase III data showing consistent efficacy.
Antibiotic Resistance
PreclinicalA key advantage of magainins is that resistance development is rare compared to conventional antibiotics. Serial passage studies show minimal MIC increase because bacteria cannot easily modify their entire membrane lipid composition to avoid AMP attack. This property makes magainins attractive as reserve antibiotics for multidrug-resistant (MDR) infections.
Anti-Biofilm Activity
PreclinicalMagainin-2 and pexiganan are active against bacterial biofilms at concentrations 2-8x MIC for planktonic bacteria. This is relevant for DFU infections, which are predominantly biofilm-associated. Activity against MRSA, Pseudomonas aeruginosa, and Candida biofilms has been demonstrated in vitro.
Calculate your Magainin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| MIC determination (broth microdilution) | 0.5-64 ug/mL | Single plate read | In vitro |
| DFU wound treatment (pexiganan) | Pexiganan 0.8% cream | Twice daily | Topical |
| Membrane permeabilization assay | 1-100 uM | Single time-point | In vitro (liposome/bacterial suspension) |
Pexiganan is the clinically developed analog. Raw magainin-2 is a research tool. Topical use only for any potential clinical application.
Interactions
Safety Profile
Topically applied pexiganan shows good local tolerability in Phase III trials with low systemic absorption. Local side effects are mild skin reactions comparable to placebo. Systemic magainin administration causes hemolysis and kidney toxicity at high doses due to membrane disruption of eukaryotic cells at high concentrations. This limits systemic use; topical and local application are the safe delivery routes. No WADA concerns.
References
- [1]Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA. 1987;84(15):5449-5453.
- [2]Lipsky BA, et al. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial. Clin Infect Dis. 2004;38(3):408-416.
- [3]Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395.